Improved Patient Collection and Retention

With Caucasian population and suitable clinical standards, the Eastern Europe present a demographically representative yet under-served clinical market for global clinical development.

The most important advantage of performing clinical trials in Eastern European countries is the patient availability for enrollment into trials. The prevalence of many on-going trials in the North America and Western Europe limits availability of patients, in particular “naïve” patients, who could be suitable for enrollment into new clinical trials.

In North American and Western European countries, it is difficult to justify in Institutional Review Board meetings why patients with existing treatment options should be placed on an unproven therapy. In many Eastern European countries, the standard of care often does not include the latest treatment options, therefore a large number of patients have had limited access to innovative therapies (e.g., biologics) and are appropriate and eager to participate in clinical trials.